MAPK3 and neoplasm: In our study, we included a substantial number of tumors with common KRAS mutations (i.e., G12D, G12V, G13D); henceforth, revealing that tumor phospho‐ERK1/2 levels are not dependent on KRAS oncogenic mutations (Fig. 1C).